These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 15700491

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS.
    BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS, Lee SH, Park KK, Yoo SJ, Chung BH.
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
    MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson DE.
    J Urol; 1999 Nov; 162(5):1629-32. PubMed ID: 10524884
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
    Türkeri LN, Ozyürek M, Ersev D, Akdaş A.
    Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M, ALF-ONE Study Group.
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI, Roehrborn CG.
    Prostate Cancer Prostatic Dis; 2007 Apr; 10(2):155-9. PubMed ID: 17211442
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA, MICTUS Study Group.
    Prostate Cancer Prostatic Dis; 2003 Feb; 6(4):315-23. PubMed ID: 14663474
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.